The new vaccine is "personalized," meaning it is designed to train the patient's immune system to recognize and eliminate any remaining cells of that person's cancer.

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

The EYLEA HD results were consistent across patients with branch retinal vein occlusions ... of EYLEA HD in its pivotal trials. Ocular treatment-emergent adverse events (TEAEs) occurring in ...

AI has quietly revolutionized the field of ophthalmology.While the concept of AI may evoke futuristic images of robots and ...

In this Healio Video Perspective from Retina 2025, W. Lloyd Clark, MD, discusses positive results from three clinical trials investigating NT-501 for macular telangiectasia type 2.

The FDA has expanded the labeling for Izervay (avacincaptad pegol) to include longer-term administration for geographic ...

HIV is a manageable chronic condition. With treatment, people living with HIV can have long and healthy lives. However, if left untreated, it can cause a weakened immune system or acquired immune ...